Mar 16, 2015 ... The case is Jones et al. v. Pfizer Inc. et al., case number 1:10-cv-03864, in the
U.S. District Court for the Southern District of New York.
WW, LLC · T-Mobile USA, Inc., et al. v. Laster, et al. ... Norman Mineta, Secretary
of the Department of Transportation) · Public Citizen. et al. v. Mineta (2d Circuit) ...
JOSE LEONARDO LOPEZ VALENCIA et al. Plaintiffs, ..... Aldana v. Del Monte
Fresh Produce, N.A., Inc.,. 416 F.3d 1242 (11th Cir. ..... Coakley v. ..... Pfizer, Inc. v
Dec 9, 2013 ... Co. v. United. States Dist. Court for Western Dist. of Tex., 571 U. S. ___. (2013).
ORDERS ... ET AL. V. COAKLEY, ATT'Y GEN. OF MA ... The motion of Owners'
Counsel of America, et al. for leave to file a brief as ... PFIZER INC., ET AL. V.
KAISER ... PAPES, MARGARET A. V. CITIMORTGAGE INC. 13-6674.
Jul 2, 2014 ... following a $73 million settlement between defendants Pfizer unit King
Pharmaceuticals, Inc. ... The case is The Shane Group, Inc., et al. v.
S91 from clinical study P03802 (Landovitz et al., 2008) receiving a regimen of
zidovudine + lamivudine ... As previously reported (Landovitz et al., 2008), VCV
plasma Cmin ...... Blanpain et al., 1999; C. Blanpain, B. Lee, J. Vakili, B.J. Doranz,
C. Govaerts, I. Migeotte, M. Sharron, V. Dupriez, .... Pfizer Inc, New York, NY (
GlaxoSmithKline, Novartis, Pfizer, Inc, Roche, and Tibotec ... Johnson VA, Calvez
V, Gunthard HF, et al. Update of the ... et al. Antiretroviral drug resistance test- ing
in adult HIV-1 infection: 2008 rec- ommendations of ...... 39. Coakley E, Chappey
C, Benhamida J, et al. Biological and clinical cut-off analyses for etravirine in ...
Apr 2, 2010 ... "A Boston federal jury ordered Pfizer to pay Kaiser Foundation $47 million for
false marketing of its drug ... Pfizer, Inc., et al., Aetna, Inc., v. Pfizer ...
Oct 3, 2013 ... For example, studies by Santos et al. ... of UBC and GH is an employee of
Evidera, both of which received funding for this research from Pfizer.
Reprinted with permission from Dorr P, Westby M, Dobbs S, et al 2005. ..... Drug
development work at Pfizer Inc. (Kent, UK) resulted in the development of UK-
427,857 .... in the maraviroc treated subjects than in the EFV treated (170 cells/
mm<sup>3</sup> vs 144 .... CA, USA) also began its commercial availability (Coakley et al